Third-quarter results from Vertex Pharmaceuticals Inc. didn't much rattle Wall Street, but some onlookers made known their uncertainty about the company's plan to start two phase II studies with next-generation correctors VX-440 and VX-152 in triple combination regimens with tezacaftor (VX-661) and Vertex's Kalydeco (ivacaftor) in cystic fibrosis (CF).